Suppr超能文献

对中枢神经系统癌症联盟的随机前瞻性试验放疗数据的分析,该试验比较了AZQ和BCNU在治疗原发性恶性脑肿瘤患者中的效果。中枢神经系统癌症联盟。

An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.

作者信息

Halperin E C, Gaspar L, Imperato J, Salter M, Herndon J, Dowling S

机构信息

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710.

出版信息

Am J Clin Oncol. 1993 Aug;16(4):277-83. doi: 10.1097/00000421-199308000-00001.

Abstract

The CNS Cancer Consortium has conducted a phase III study comparing diaziquone (AZQ) with carmustine (BCNU) in the treatment of adults with primary anaplastic glial brain tumors. Patients eligible for this study were 18 years of age or older at the time of biopsy, subtotal resection, or gross total resection of an anaplastic glial brain tumor. Within 3 weeks of surgery, patients received whole brain radiotherapy at 1.7 to 2 Gy per fraction to a total whole brain dose of 42-48 Gy. This was followed by a boost to the tumor bed as ascertained by computed tomography (CT), angiography, and/or magnetic resonance imaging (MRI) of 1.7 to 2 Gy per fraction to a dose of 12-19 Gy. The recommended cumulative dose to the tumor bed was therefore 55-61 Gy. At 8 weeks following radiotherapy, patients were randomized to receive either AZQ at 15 mg/day for 3 days i.v. every 4 weeks or BCNU at 200 mg i.v. every 8 weeks. Chemotherapy was continued for at least 1 year unless death occurred, treatment failure was declared, or toxicity necessitated alteration of therapy. In the 249 randomized patients, there was no difference between the AZQ- and BCNU-treated patients in age, sex distribution, race, tumor histology, type of surgical resection, or Karnofsky performance status (KPS). Age and KPS at the initiation of therapy and tumor histology were the best overall predictors of survival. The type of chemotherapy (AZQ vs BCNU) was not predictive of survival. Two-year Kaplan-Meier survival was 22% in the AZQ-treated patients and 25% in BCNU-treated patients. In an analysis of radiotherapy administered we found that, within the range of doses required for this study, there was no influence of whole brain dose, boost dose, total dose, or size of the boost field on survival. The institution providing radiotherapy (teaching hospital vs nonteaching facility) did not influence survival.

摘要

中枢神经系统癌症联盟开展了一项III期研究,比较二氮嗪醌(AZQ)与卡莫司汀(BCNU)治疗原发性间变性胶质细胞瘤成人患者的疗效。符合本研究条件的患者在间变性胶质细胞瘤活检、次全切除或全切除时年龄为18岁或以上。在手术后3周内,患者接受全脑放疗,每次分割剂量为1.7至2 Gy,全脑总剂量为42 - 48 Gy。随后根据计算机断层扫描(CT)、血管造影和/或磁共振成像(MRI)确定肿瘤床情况,每次分割剂量为1.7至2 Gy,剂量为12 - 19 Gy进行瘤床加量照射。因此,瘤床的推荐累积剂量为55 - 61 Gy。放疗后8周,患者被随机分为两组,一组每4周静脉注射AZQ 15 mg/天,共3天;另一组每8周静脉注射BCNU 200 mg。化疗持续至少1年,除非发生死亡、宣布治疗失败或毒性反应需要改变治疗方案。在249例随机分组的患者中,接受AZQ治疗和接受BCNU治疗的患者在年龄、性别分布、种族、肿瘤组织学、手术切除类型或卡诺夫斯基功能状态(KPS)方面没有差异。治疗开始时的年龄和KPS以及肿瘤组织学是生存的最佳总体预测因素。化疗类型(AZQ与BCNU)不能预测生存情况。接受AZQ治疗的患者两年的卡普兰 - 迈耶生存率为22%,接受BCNU治疗的患者为25%。在对所给予的放疗进行分析时,我们发现,在本研究所需的剂量范围内,全脑剂量、加量剂量、总剂量或加量野大小对生存没有影响。提供放疗的机构(教学医院与非教学机构)对生存没有影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验